We are live on ! Find out more
PRNB

Principia Biopharma Inc. Common Stock
PRNB

Delisted

PRNB was delisted on the 25th of September, 2020.

81 hedge funds and large institutions have $569M invested in Principia Biopharma Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 23 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

43% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 23

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

9% more funds holding

Funds holding: 7481 (+7)

15% less capital invested

Capital invested by funds: $671M → $569M (-$102M)

Holders
81
Holders Change
+7
Holders Change %
+9.46%
% of All Funds
1.77%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
14
Increased
33
Reduced
23
Closed
7
Calls
Puts
Net Calls
Net Calls Change

PRNB Hedge Fund Activity: Q3 2019 in Review

81 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Principia Biopharma Inc. Common Stock (PRNB) for Q3 2019, worth a combined $569M — down 15% from $671M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PRNB positions and 7 closed out — a net gain of 7 holders — while 33 added to existing stakes and 23 trimmed.

The largest buyer was Redmile Group, adding an estimated $20M. The largest seller was New Leaf Venture Partners, cutting an estimated $23.1M.

  • 81 institutional investors held Principia Biopharma Inc. Common Stock (PRNB) as of Q3 2019, up from 74 in Q2 2019.
  • Funds reported $569M of Principia Biopharma Inc. Common Stock stock for Q3 2019, down 15% quarter-over-quarter.
  • 14 funds opened new Principia Biopharma Inc. Common Stock positions in Q3 2019 and 7 closed out, a net change of +7 holders.
  • The largest Principia Biopharma Inc. Common Stock buyer in Q3 2019 was Redmile Group, an estimated $20M added.
  • The largest Principia Biopharma Inc. Common Stock seller in Q3 2019 was New Leaf Venture Partners, an estimated $23.1M sold.

Based on aggregated 13F filings for Q3 2019.